The U.S. Trustee, the bankruptcy arm of the Justice Department, will appoint one or more committees to represent the interests of creditors and stockholders in working with the company to develop a plan of reorganization to get out of debt.
Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH).
For example, the orphan drug Soliris has an average annual cost of up to $488,000 per patient for the treatment of paroxysmal nocturnal hemoglobinuria â one of two ultra-rare diseases for which it is approved. It netted $2.59 billion in sales last year.